| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10428190801993504 |
| P698 | PubMed publication ID | 18452076 |
| P50 | author | Hervé Dombret | Q66385559 |
| P2093 | author name string | Xavier Thomas | |
| P2860 | cites work | Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 |
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | Q28246204 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome | Q33181755 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias | Q33343973 | ||
| The biology of chronic myeloid leukemia | Q33686190 | ||
| Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults | Q34186610 | ||
| Philadelphia chromosome-positive acute lymphocytic leukemia | Q34189733 | ||
| VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo | Q34300737 | ||
| Active transport of imatinib into and out of cells: implications for drug resistance | Q34341750 | ||
| Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study | Q34627586 | ||
| A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells | Q35045183 | ||
| Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back | Q35128883 | ||
| Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia | Q35782565 | ||
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia | Q35945171 | ||
| Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Q40458599 | ||
| Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients | Q40671094 | ||
| Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia | Q41125612 | ||
| Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. | Q41740883 | ||
| Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia | Q42169518 | ||
| Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia | Q43617176 | ||
| Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 | ||
| Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study | Q43863915 | ||
| Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. | Q44072012 | ||
| Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial | Q44142813 | ||
| Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia | Q44161659 | ||
| Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). | Q44231537 | ||
| BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. | Q44267685 | ||
| The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia | Q44318362 | ||
| Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines | Q44491942 | ||
| Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). | Q44598654 | ||
| Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate | Q44612967 | ||
| Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia | Q44851706 | ||
| Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. | Q44906233 | ||
| Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation | Q45166922 | ||
| Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome | Q46374584 | ||
| Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). | Q46427718 | ||
| Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib | Q46735050 | ||
| High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group | Q46847866 | ||
| Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission | Q47596662 | ||
| Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. | Q50970578 | ||
| Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. | Q52958934 | ||
| Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. | Q53029629 | ||
| Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. | Q54574746 | ||
| A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. | Q54773417 | ||
| Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study | Q56997440 | ||
| Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) | Q58023972 | ||
| Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 | ||
| Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414415 | ||
| A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia | Q59060532 | ||
| Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia | Q59085791 | ||
| P433 | issue | 7 | |
| P921 | main subject | Philadelphia chromosome | Q1129111 |
| P304 | page(s) | 1246-1254 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia | |
| P478 | volume | 49 |
| Q39690602 | Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia | cites work | P2860 |
Search more.